Purpose
The purpose of Bamlanivimab for Emergency Passive Immunity against COVID-19 (B-EPIC),
a randomized, phase 4 clinical trial, is to determine whether the drug bamlanivimab can reduce the number of hospitalizations in high-risk patients diagnosed with COVID-19. B-EPIC is led by Dr. Gregory Haljan, Regional Medical Director for Research in Fraser Health, and Critical Care Department Head at Surrey Memorial Hospital. The data from this study will inform clinical decisions about the use of bamlanivimab in high risk COVID-19 patients and the operational requirements necessary for future research in passive immunity therapeutics.
Our Involvement
Our team is supporting B-EPIC through REDCap for data entry and storage.
Services Used
Electronic Data Collection